全球菌落刺激因子市场 – 行业趋势和 2030 年预测

菌落刺激因子市场分析和规模

集落刺激因子 (Colony Stimulating Factors) 是一种激素样蛋白质，可促进产生抵抗感染的免疫细胞。集落刺激因子由我们体内的多种细胞产生，可​​在整个身体内传播，与具有专门集落刺激因子受体的细胞结合。集落刺激因子被用作促进白细胞形成的药物，因为它们可以刺激免疫细胞的合成。对于那些免疫系统因化疗或某些免疫缺陷疾病而受到严重破坏的人来说，这可能是一种挽救生命的治疗方法。集落刺激因子也是用于移植血液干细胞的重要药物。                               

Data Bridge Market Research 分析，集落刺激因子市场规模将从 2022 年的 77.2 亿美元飙升至 2030 年的 174.2 亿美元，预计在预测期内的复合年增长率为 10.70%。由于各种慢性疾病经常需要进行骨髓移植，“骨髓移植”在集落刺激因子市场的应用领域中占据主导地位。

除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的洞察之外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

市场定义

为了应对感染，集落刺激因子是一种糖蛋白，可促进白细胞（主要是粒细胞，如中性粒细胞）的发育。外源性集落刺激物质可刺激骨髓中的干细胞产生更多特定类型的白细胞。新的白细胞进入血液并开始对抗疾病。接受癌症治疗的患者白细胞计数低（中性粒细胞减少症）并面临感染风险，因此需要接受集落刺激剂。接受集落刺激物质的患者中性粒细胞减少的时间较短。            

全球菌落刺激因子市场动态

驱动程序

• 血液病患病率不断上升

The prevalence of hematological disorders, such as leukemia and anemia, has been on the rise globally. Colony Stimulating Factors are used in the treatment of these conditions to stimulate the production of blood cells. The increasing incidence of such disorders is a significant driver for the colony stimulating factors market.

• Growing aging population

As the global population continues to age, there is an increased demand for therapies that can address age-related conditions, including those related to the hematopoietic system. This demographic shift has contributed to the growth of the colony stimulating factors market, as elderly individuals are more prone to hematological disorders.

• Advancements in biotechnology and healthcare 

Advances in biotechnology, including the development of biosimilars, have played a pivotal role in the colony stimulating factors market's expansion. Biosimilars offer more cost-effective options for colony stimulating factors therapy, making them more accessible to a broader patient base.

• Growing investment for healthcare facilities

Surging focus towards improving the condition of healthcare facilities and improving the overall healthcare infrastructure another important factor fostering the growth of the market. Rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Expansion of emerging markets

Emerging markets, especially in Asia and Latin America, have shown a growing demand for healthcare services. The increasing awareness of colony stimulating factors and their potential in treating hematological disorders in these regions presents a significant growth opportunity for global Colony Stimulating Factors manufacturers.

• Development of Novel Colony Stimulating Factors Therapies

Research and development in the field of biotechnology and immunology can lead to the development of novel colony stimulating factors therapies. Innovations such as longer-acting colony stimulating factors, personalized medicine approaches, or new delivery methods can open up new avenues in the market and improve patient outcomes.

Restraints

• High treatment costs

Colony stimulating factors therapies can be expensive, which may limit access to these treatments for some patients, especially in regions with limited healthcare resources. The high cost of colony stimulating factors can be a significant restraint on market growth.

• Stringent regulatory requirements

Stringent regulatory requirements for the approval of new colony stimulating factors products can be a restraint. Companies face hurdles in navigating complex and evolving regulatory pathways, leading to delays in product launches and increased development costs.

Challenges

• Potential adverse effects

Colony stimulating factors therapy can have side effects, including bone pain, fever, and allergic reactions. These adverse effects can limit the use of colony stimulating factors in certain patient populations, and concerns about safety and tolerability can be a challenge for market expansion.

• Limited awareness and access

In some regions, there may be limited awareness about colony stimulating factors therapies, leading to underdiagnosis and undertreatment of hematological disorders. Additionally, unequal access to healthcare resources can hinder patient access to colony stimulating factors treatments, creating challenges for market growth.

This colony stimulating factors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the colony stimulating factors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In March 2023, Coherus BioSciences received U.S. FDA approval for its pegfilgrastim-cbqv (Udencya), a pegfilgrastim biosimilar for managing febrile neutropenia induced by chemotherapy.
• In September 2022, Spectrum Pharmaceuticals, Inc. received U.S. FDA approval for its ROLVEDON (eflapegrastim-xnst) injection, which is intended to decrease the incidence of infection, as manifested by febrile neutropenia in adult patients with non-myeloid-malignancies-receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Global Colony stimulating factors Market Scope

The colony stimulating factors market is segmented on the basis of type, drug, application, dosage, route of administration, end-users and distribution channel analysis. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Macrophage–Colony-Stimulating Factor (M-CSF)
• Multiple-Colony-Stimulating Factor, or Interleukin 3 (IL-3)
• Granulocyte-Macrophage–Colony-Stimulating Factor (GM-CSF)
• Granulocyte–Colony-Stimulating Factor (G-CSF)

Drug

• Pegfilgrastim
• Tbo-filgrastim
• Sargramostim
• Filgrastim

Application

• Aplastic Anemia
• Bone Marrow Transplantation
• Neutropenia
• Neutropenia Associated with Chemotherapy
• Neutropenia Associated with Radiation
• Peripheral Progenitor Cell Transplantation

Dosage

• Injection
• Tablets
• Capsule
• Others

Route of Administration

• Intravenous
• Subcutaneous
• Oral
• Others

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Colony stimulating factors Market Regional Analysis/Insights

The colony stimulating factors market is analysed and market size insights and trends are provided by country, type, drug, application, dosage, route of administration, end-users and distribution channel analysis as referenced above.

The countries covered in the colony stimulating factors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the colony stimulating factors market because of the rising prevalence of cancer in this region. Additionally, the growing presence of major key players and well-established healthcare infrastructure will further propel the market’s growth rate.

Asia-Pacific region is expected to grow during the forecast period of 2022-2029 due to rising healthcare expenditure and improvements in healthcare infrastructure in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The colony stimulating factors market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for colony stimulating factors market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the colony stimulating factors market. The data is available for historic period 2010-2020.

Competitive Landscape and Colony stimulating factors Market Share Analysis

集落刺激因子市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对集落刺激因子市场的关注有关。

菌落刺激因子市场的一些主要参与者包括：

• Intas Pharmaceuticals Ltd.（印度）
• 赛诺菲（法国）
• 诺华公司（瑞士）
• Teva Pharmaceutical Industries Ltd.（爱尔兰）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• Biocon（印度）
• Dr. Reddy's Laboratories Ltd.（印度）
• 安进公司 (美国)
• 默克集团（德国）
• 武田药品工业株式会社 (日本)
• 赛默飞世尔科技公司（美国）
• STADA Arzneimittel AG（德国）
• Emcure Pharmaceuticals Limited.（印度）
• CELLTRION INC.（韩国）
• BIOCAD（俄罗斯）
• Coherus BioSciences（美国） 
• 强生私人有限公司（美国）
• 礼来公司 (美国)
• 雅培（美国）

SKU-68380